Spark Therapeutics’ chief medical officer Kathy Reape is set to leave the biotech. Reape is one of the senior Spark staffers hitting the exit in the aftermath of Roche’s $4.3 billion takeover.
Kathy High, Spark’s co-founder and R&D head, is the highest-profile person to depart the biotech in the wake of Roche’s takeover, but FierceBiotech has learned she is not the only person to decide their future lies elsewhere. Perhaps most notably, Reape is set to follow High out of the door.
“We can confirm that Kathy Reape, M.D., has made us aware that her time with Spark Therapeutics is coming to an end and we can confirm she is leaving the company. Dr. Reape has been a valuable member of Spark in her time with the company and leaves behind a skilled team of professionals who will continue advancing our important work for patients and families,” a spokesperson for Roche said.
Reape joined Spark as head of clinical R&D in 2016, rising to the position of CMO two years later. The role gave Reape oversight of clinical, pharmacovigilance and medical affairs activities at Spark. With Spark now part of Roche, Reape has decided to end her four-year stay at the gene therapy specialist.
Spark is yet to publish a job advert for the CMO post but has begun the process of filling other gaps in its leadership team. Listings for a head of regulatory affairs and head of quality assurance went live last week.
Dan Takefman has served as Spark’s head of regulatory affairs since 2014, when he ended a 15-year spell at the FDA. The head of quality assurance position is currently held by Michael Cowan, who joined Spark from Aralez Pharmaceuticals in 2016.
Roche is yet to confirm whether Takefman or Cowan are leaving Spark. However, the source who told FierceBiotech of Reape’s departure also said Spark’s head of regulatory affairs is leaving the biotech.
In confirming the departures of High and Reape, Roche has consistently noted the depth of talent at Spark. However, the post-takeover period is a time of change for Spark. As it stands, Spark, which has around 450 employees, is recruiting for 69 positions. Some of the job adverts are seeking new people to fill existing positions, such as the head of regulatory affairs post. In other cases, Spark is recruiting for newly created positions, including that of head of technology automation.
By Nick Paul Taylor
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
